Drug Trial Radar · NCT06846437
JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
Last checked: Nov 20, 2026Latest source record: Mar 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
228
Planned (sponsor's estimate)
Start
Feb 18, 2025
Primary completion
Oct 13, 2026
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Shanghai JMT-Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to compare the safety and efficacy of JSKN003 versus T-DM1 in unrespectable locally advanced and/or metastatic HER2-positive breast cancer participants previously treated with trastuzumab and taxane.
Conditions
- Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
Interventions
JSKN003Drug
Administered intravenously according to protocol.
Trastuzumab emtansine (T-DM1)Drug
Administered intravenously according to the approved label.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) by BIRCTime frame: Up to approximately 4 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.